A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Centinel Spine® Announces First International Use of 3D-Printed Porous Titanium FLX™ Platform

Centinel Spine®, LLC, a leading global medical device company addressing cervical and lumbar spinal disease through anterior surgical access, today announced the first international implantation of the 3D-Printed Porous Titanium FLX™ platform. Dr. Alfredo Guiroy and Dr. Jose Ricardo Prina in Argentina were the first surgeons outside the United States to implant the STALIF C FLX™ and STALIF M FLX™ devices.

The FLX platform represents the latest material evolution offered by Centinel Spine. The STALIF C FLX and STALIF M FLX devices are 3D-printed porous titanium Integrated Interbody™ implants that have been engineered to mimic bone. These implants provide equivalent subsidence performance to PEEK; contain a proprietary, interconnected FUSE-THRU™ lattice with a structure and modulus of elasticity similar to bone; and have optimized mechanical, visual, and osteophilic environments that reduce stress shielding, enable fusion assessment, and support bony in-growth, on-growth, and thru-growth.

“The STALIF M FLX cage has a bone contact surface much better and larger than any other PEEK cage of the same size and has a maximum capability of osteointegration with the bone,” said Dr. Prina. “We consider that this works much better for a stand-alone procedure.”

“It is my pleasure to use STALIF®. It’s a very good implant, with a lot of versatility due to different sizes and lordotic options, and titanium has shown to be more friendly for fusion than other PEEK/hybrid combinations,” commented Dr. Guiroy.

Centinel Spine’s CEO, Steve Murray, stated, “We are excited to be able to offer our state-of-the-art FLX technology to our international partners. As a company, we remain dedicated to continued innovation and furthering scientific evidence in advancing spine care. We are proud to be able to make our technology available to even more patients on a global scale.”

STALIF M FLX and STALIF C FLX implants are built upon the proven STALIF design, which has over 30 years of clinical history and has helped many patients regain their lives. STALIF implants provide compressive fixation at the fusion site, pulling the vertebral bodies onto the implant and graft material to enhance opportunities for fusion in line with Wolff’s Law of Bone Healing.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Sachita Shah, Sr. Director, Global Health, Butterfly Network, "Butterfly is proud to continue improving maternal health equity through Phase Two of the largest-scale handheld ultrasound distribution and training ever conducted in Sub-Saharan Africa. South Africa is an emerging market that continues to have disproportionately high rates of maternal mortality and stillbirth. Patients need easier access to antenatal imaging, and clinicians need better capabilities for screening high-risk conditions that lead to disproportionately worse pregnancy outcomes in rural areas in the public sector. Together with CHAI and GUSI, we can tackle this by making ultrasound much more accessible, so high-risk conditions can be identified earlier in care, which is known to improve outcomes.”
The clinical Study will enroll up to 97 patients at up to 12 European investigational sites. Completion of the study is expected this year, and results will support CE mark and pre-market approval submissions reports Vivasure Medical.
Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.

By using this website you agree to accept Medical Device News Magazine Privacy Policy